Titan Pharmaceuticals Inc (TTNP)

[Serenity3]

New Pain Management and Buprenorphine Regulations .. from the Virginia Board of Medicine newsletter .. May 2017..
“1. Can I continue to prescribe mono-product for my patients that have a demonstrated intolerance to naloxone –containing products? The answer by the current regulations is NO. There is no exception in the regulations that would permit prescribing of the mono-product in tablet form for naloxone intolerance or allergy. However, the buprenorphine mono-product may be prescribed in FDA-approved “formulations other than tablet form” pursuant to 18 VAC 85-21-150(A)(3). The Board of Medicine will consider this issue in the near future, and if a revision is made, it will be circulated to prescribers. 2. What alternatives to buprenorphine mono-product for addiction are there? This is not an endorsement for a particular medication, and there may be other alternatives unknown to the Board at this time. The only other mono-product currently FDA-approved for the treatment of addiction is the Probuphine implant. Formulations with low-dose naloxone include Zubsolv sublingual tablets and Bunavail buccal film. Methadone and Vivitrol are also options.”
https://www.dhp.virginia.gov/medicine/newsletters/BoardBrief83.pdf